Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15249677 
Liu F, et al. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101, 10804-9 15249677
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S199-p - Tau iso8 (human)
Orthologous residues
Tau (human): S516‑p, Tau iso2 (human): S141‑p, Tau iso3 (human): S105‑p, Tau iso5 (human): S199‑p, Tau iso6 (human): S141‑p, Tau iso7 (human): S170‑p, Tau iso8 (human): S199‑p, Tau (mouse): S491‑p, Tau iso3 (mouse): S188‑p, Tau iso7 (mouse): S148‑p, Tau (rat): S510‑p, Tau (cow): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase
low glucose increase in medium containing 1.4 mM instead of the normal 11 mM glucose

S202-p - Tau iso8 (human)
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase
low glucose increase in medium containing 1.4 mM instead of the normal 11 mM glucose

T205-p - Tau iso8 (human)
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase
low glucose increase in medium containing 1.4 mM instead of the normal 11 mM glucose

T212-p - Tau iso8 (human)
Orthologous residues
Tau (human): T529‑p, Tau iso2 (human): T154‑p, Tau iso3 (human): T118‑p, Tau iso5 (human): T212‑p, Tau iso6 (human): T154‑p, Tau iso7 (human): T183‑p, Tau iso8 (human): T212‑p, Tau (mouse): T504‑p, Tau iso3 (mouse): T201‑p, Tau iso7 (mouse): T161‑p, Tau (rat): T523‑p, Tau (cow): T219‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase
low glucose increase in medium containing 1.4 mM instead of the normal 11 mM glucose

S214-p - Tau iso8 (human)
Orthologous residues
Tau (human): S531‑p, Tau iso2 (human): S156‑p, Tau iso3 (human): S120‑p, Tau iso5 (human): S214‑p, Tau iso6 (human): S156‑p, Tau iso7 (human): S185‑p, Tau iso8 (human): S214‑p, Tau (mouse): S506‑p, Tau iso3 (mouse): S203‑p, Tau iso7 (mouse): S163‑p, Tau (rat): S525‑p, Tau (cow): S221‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase

T217-p - Tau iso8 (human)
Orthologous residues
Tau (human): T534‑p, Tau iso2 (human): T159‑p, Tau iso3 (human): T123‑p, Tau iso5 (human): T217‑p, Tau iso6 (human): T159‑p, Tau iso7 (human): T188‑p, Tau iso8 (human): T217‑p, Tau (mouse): T509‑p, Tau iso3 (mouse): T206‑p, Tau iso7 (mouse): T166‑p, Tau (rat): T528‑p, Tau (cow): T224‑p

S262-p - Tau iso8 (human)
Orthologous residues
Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase

S396-p - Tau iso8 (human)
Orthologous residues
Tau (human): S713‑p, Tau iso2 (human): S307‑p, Tau iso3 (human): S271‑p, Tau iso5 (human): S365‑p, Tau iso6 (human): S338‑p, Tau iso7 (human): S367‑p, Tau iso8 (human): S396‑p, Tau (mouse): S688‑p, Tau iso3 (mouse): S385‑p, Tau iso7 (mouse): S345‑p, Tau (rat): S707‑p, Tau (cow): S403‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
streptozotocin okadaic acid inhibit treatment-induced increase
PUGNAc okadaic acid inhibit treatment-induced increase
low glucose increase in medium containing 1.4 mM instead of the normal 11 mM glucose

S404-p - Tau iso8 (human)
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  regulated by O-GlcNAcylation (phosphorylation of site decreased by O-GlcNAcylation)

S422-p - Tau iso8 (human)
Orthologous residues
Tau (human): S739‑p, Tau iso2 (human): S333‑p, Tau iso3 (human): S297‑p, Tau iso5 (human): S391‑p, Tau iso6 (human): S364‑p, Tau iso7 (human): S393‑p, Tau iso8 (human): S422‑p, Tau (mouse): S714‑p, Tau iso3 (mouse): S411‑p, Tau iso7 (mouse): S371‑p, Tau (rat): S733‑p, Tau (cow): S429‑p

S491-p - Tau (mouse)
Orthologous residues
Tau (human): S516‑p, Tau iso2 (human): S141‑p, Tau iso3 (human): S105‑p, Tau iso5 (human): S199‑p, Tau iso6 (human): S141‑p, Tau iso7 (human): S170‑p, Tau iso8 (human): S199‑p, Tau (mouse): S491‑p, Tau iso3 (mouse): S188‑p, Tau iso7 (mouse): S148‑p, Tau (rat): S510‑p, Tau (cow): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation increase

S494-p - Tau (mouse)
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation no change compared to control

T497-p - Tau (mouse)
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation increase

T504-p - Tau (mouse)
Orthologous residues
Tau (human): T529‑p, Tau iso2 (human): T154‑p, Tau iso3 (human): T118‑p, Tau iso5 (human): T212‑p, Tau iso6 (human): T154‑p, Tau iso7 (human): T183‑p, Tau iso8 (human): T212‑p, Tau (mouse): T504‑p, Tau iso3 (mouse): T201‑p, Tau iso7 (mouse): T161‑p, Tau (rat): T523‑p, Tau (cow): T219‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation increase

S506-p - Tau (mouse)
Orthologous residues
Tau (human): S531‑p, Tau iso2 (human): S156‑p, Tau iso3 (human): S120‑p, Tau iso5 (human): S214‑p, Tau iso6 (human): S156‑p, Tau iso7 (human): S185‑p, Tau iso8 (human): S214‑p, Tau (mouse): S506‑p, Tau iso3 (mouse): S203‑p, Tau iso7 (mouse): S163‑p, Tau (rat): S525‑p, Tau (cow): S221‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation decrease

T509-p - Tau (mouse)
Orthologous residues
Tau (human): T534‑p, Tau iso2 (human): T159‑p, Tau iso3 (human): T123‑p, Tau iso5 (human): T217‑p, Tau iso6 (human): T159‑p, Tau iso7 (human): T188‑p, Tau iso8 (human): T217‑p, Tau (mouse): T509‑p, Tau iso3 (mouse): T206‑p, Tau iso7 (mouse): T166‑p, Tau (rat): T528‑p, Tau (cow): T224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation increase

S688-p - Tau (mouse)
Orthologous residues
Tau (human): S713‑p, Tau iso2 (human): S307‑p, Tau iso3 (human): S271‑p, Tau iso5 (human): S365‑p, Tau iso6 (human): S338‑p, Tau iso7 (human): S367‑p, Tau iso8 (human): S396‑p, Tau (mouse): S688‑p, Tau iso3 (mouse): S385‑p, Tau iso7 (mouse): S345‑p, Tau (rat): S707‑p, Tau (cow): S403‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation increase

S696-p - Tau (mouse)
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose starvation no change compared to control

S510-p - Tau (rat)
Orthologous residues
Tau (human): S516‑p, Tau iso2 (human): S141‑p, Tau iso3 (human): S105‑p, Tau iso5 (human): S199‑p, Tau iso6 (human): S141‑p, Tau iso7 (human): S170‑p, Tau iso8 (human): S199‑p, Tau (mouse): S491‑p, Tau iso3 (mouse): S188‑p, Tau iso7 (mouse): S148‑p, Tau (rat): S510‑p, Tau (cow): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase

S513-p - Tau (rat)
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid augment treatment-induced increase

T516-p - Tau (rat)
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid no effect upon treatment-induced increase

T523-p - Tau (rat)
Orthologous residues
Tau (human): T529‑p, Tau iso2 (human): T154‑p, Tau iso3 (human): T118‑p, Tau iso5 (human): T212‑p, Tau iso6 (human): T154‑p, Tau iso7 (human): T183‑p, Tau iso8 (human): T212‑p, Tau (mouse): T504‑p, Tau iso3 (mouse): T201‑p, Tau iso7 (mouse): T161‑p, Tau (rat): T523‑p, Tau (cow): T219‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase

S525-p - Tau (rat)
Orthologous residues
Tau (human): S531‑p, Tau iso2 (human): S156‑p, Tau iso3 (human): S120‑p, Tau iso5 (human): S214‑p, Tau iso6 (human): S156‑p, Tau iso7 (human): S185‑p, Tau iso8 (human): S214‑p, Tau (mouse): S506‑p, Tau iso3 (mouse): S203‑p, Tau iso7 (mouse): S163‑p, Tau (rat): S525‑p, Tau (cow): S221‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid augment treatment-induced increase

T528-p - Tau (rat)
Orthologous residues
Tau (human): T534‑p, Tau iso2 (human): T159‑p, Tau iso3 (human): T123‑p, Tau iso5 (human): T217‑p, Tau iso6 (human): T159‑p, Tau iso7 (human): T188‑p, Tau iso8 (human): T217‑p, Tau (mouse): T509‑p, Tau iso3 (mouse): T206‑p, Tau iso7 (mouse): T166‑p, Tau (rat): T528‑p, Tau (cow): T224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase

S573-p - Tau (rat)
Orthologous residues
Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase

S707-p - Tau (rat)
Orthologous residues
Tau (human): S713‑p, Tau iso2 (human): S307‑p, Tau iso3 (human): S271‑p, Tau iso5 (human): S365‑p, Tau iso6 (human): S338‑p, Tau iso7 (human): S367‑p, Tau iso8 (human): S396‑p, Tau (mouse): S688‑p, Tau iso3 (mouse): S385‑p, Tau iso7 (mouse): S345‑p, Tau (rat): S707‑p, Tau (cow): S403‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase

S715-p - Tau (rat)
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid augment treatment-induced increase

S733-p - Tau (rat)
Orthologous residues
Tau (human): S739‑p, Tau iso2 (human): S333‑p, Tau iso3 (human): S297‑p, Tau iso5 (human): S391‑p, Tau iso6 (human): S364‑p, Tau iso7 (human): S393‑p, Tau iso8 (human): S422‑p, Tau (mouse): S714‑p, Tau iso3 (mouse): S411‑p, Tau iso7 (mouse): S371‑p, Tau (rat): S733‑p, Tau (cow): S429‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase
PUGNAc okadaic acid inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.